To select the most appropriate HER2+ breast cancer and TNBC cell lines to conduct RNAi screening, we determined the anti-proliferation effect of neratinib in 8 HER2+ breast cancer and 13 TNBC cell lines. Here, ERBB2 is linked to breast carcinoma.